Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Bicalutamide + Gonadorelin |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Bicalutamide | Casodex | Hormone - Anti-androgens 54 | Casodex (bicalutamide) is an androgen-receptor antagonist that binds androgen receptors and inhibits androgen binding, therefore inhibits AR-dependent growth of tumor cells (PMID: 9428389). Casodex (bicalutamide) is approved, in combination with a luteinizing hormone-releasing hormone (LHRH) analog, for metastatic carcinoma of the prostate (FDA.gov). | |
Gonadorelin | Dirigestran|GnRH|LHRHA|AY-24031 | Hormone Antineoplastics 2 | Gonadorelin is a synthetic version of gonatotropin-releasing hormone (GnRH) that binds GnRH receptors and induces gonatotropic hormone release, and leads to down-regulation of GnRH receptor expression and reduced hormone release following sustained exposure (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03141671 | Phase II | Bicalutamide + Gonadorelin Abiraterone + Apalutamide + Gonadorelin + Prednisone | Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509) | Active, not recruiting | USA | 0 |